1. Molecular confirmation of alpha 1-antitrypsin deficiency in liver transplant setting: A province-wide experience.
- Author
-
Bukhari, Hussam, Mattman, Andre, Ritchie, Gordon, Burns, Laura, Yoshida, Eric, Schaeffer, David, and Hui-Min Yang
- Subjects
ALPHA 1-antitrypsin deficiency ,LIVER transplantation ,GENE frequency ,ALLELES ,LIVER diseases ,LIVER disease diagnosis ,POLYMERASE chain reaction - Abstract
Background and Aim: Patients suspected of Alpha 1-Antitrypsin (A1AT) abnormality based on low serum concentration are routinely confirmed through polymerase chain reaction (PCR) testing of peripheral blood. Genotyping formalin- fixed paraffin-embedded (FFPE) tissue is a novel approach that could aid in detecting variant A1AT. We performed qPCR on FFPE liver explants with Periodic Acid Schiff after Diastase (PASD)- and A1AT-positive globules to confirm and estimate the frequency of A1AT deficiency in transplant cases. Materials and Methods: Eighteen (12.68%) of 142 patients with end-stage liver disease showed PASD/A1AT positive globules. FFPE of the explants was tested through qPCR to detect S and Z alleles. A second age- and sex-matched control group consisting of five liver transplant patients with negative globules was included in the study. Results: qPCR assay was successful with all the samples meeting QC parameters. All patients included in the study elucidated Z allele variants; 2 homozygous (11.1%) and 16 heterozygous (88.9%). The control group demonstrated normal wild-type MM allele. Conclusion: Screening for A1AT deficiency using serum levels is not sufficiently sensitive to detect deficiency, especially in carriers. If A1AT testing was not performed preoperatively and the risk is high based on the PASD/ A1AT-positive globules in the explants, then molecular testing of FFPE tissue can be a viable method for confirming the diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF